Company intelligence / Profile preview

Aegle Medical

Miami, Florida, United Statesaeglemedicalsolutions.com ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

AGLE-102 has shown preclinical efficacy by inducing production of collagen VII in DEB fibroblasts and delivering functional proteins to support tissue regeneration. Phase 1/2 trial now enrolling patients with RDEB; no published late-stage results yet.

Therapeutic areas: DermatologyImmunology
Modalities: Extracellular vesicle therapy (EV therapy)Exosome-based therapy
Industry: Biotech

Beyond the preview

Go deeper on Aegle Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aegle Medical.

Explore the full profile